Daratumumab: new indications revolving around "off-targets".
作者信息
Ofran Yishai
机构信息
Hebrew University Faculty of Medicine, Department of Hematology, Shaare Zedek Medical Center, Jerusalem.
出版信息
Haematologica. 2021 Dec 1;106(12):3032-3033. doi: 10.3324/haematol.2021.279487.
Abstract
摘要
相似文献
1
Daratumumab: new indications revolving around "off-targets".达雷妥尤单抗：围绕“非靶向”的新适应症
Haematologica. 2021 Dec 1;106(12):3032-3033. doi: 10.3324/haematol.2021.279487.
2
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.达雷妥尤单抗：一种用于治疗多发性骨髓瘤的首创CD38单克隆抗体。
J Hematol Oncol. 2016 Jun 30;9(1):51. doi: 10.1186/s13045-016-0283-0.
3
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.达雷妥尤单抗对CD38的长期饱和作用会干扰骨髓瘤细胞的诊断检测。
Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18.
4
Loss of CD38 expression in myelomatous pleural effusion in a patient with myeloma treated with daratumumab: Report of a case.达雷妥尤单抗治疗的骨髓瘤患者出现骨髓瘤性胸腔积液中CD38表达缺失：一例报告
Diagn Cytopathol. 2021 Jan;49(1):168-170. doi: 10.1002/dc.24630. Epub 2020 Oct 1.
5
Daratumumab in Primary Effusion Lymphoma.达雷妥尤单抗治疗原发性渗出性淋巴瘤
N Engl J Med. 2018 Aug 16;379(7):689-690. doi: 10.1056/NEJMc1806295.
6
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.治疗前CD38阳性调节性T细胞影响复发/难治性多发性骨髓瘤患者对达雷妥尤单抗的持久反应。
Haematologica. 2020 Jan;105(1):e37-e40. doi: 10.3324/haematol.2019.219683. Epub 2019 Apr 19.
7
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.DNA甲基转移酶抑制剂上调CD38蛋白表达并增强达雷妥尤单抗在多发性骨髓瘤中的疗效。
Leukemia. 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.
8
Daratumumab for the treatment of multiple myeloma.达雷妥尤单抗用于治疗多发性骨髓瘤。
Expert Opin Biol Ther. 2017 Jul;17(7):887-893. doi: 10.1080/14712598.2017.1322578. Epub 2017 May 2.
9
Could daratumumab be used to treat severe allergy?达雷妥尤单抗可用于治疗严重过敏吗？
J Allergy Clin Immunol. 2017 May;139(5):1677-1678.e3. doi: 10.1016/j.jaci.2016.12.955. Epub 2017 Jan 19.
10
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.CD38 复合物的晶体结构，其中 daratumumab 是一种治疗多发性骨髓瘤的首创抗 CD38 抗体药物。
Biochem Biophys Res Commun. 2021 Jan 15;536:26-31. doi: 10.1016/j.bbrc.2020.12.048. Epub 2020 Dec 22.
引用本文的文献
1
Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review.造血干细胞移植中的输血支持：当代叙述性综述
Clin Hematol Int. 2024 Mar 25;6(1):128-140. doi: 10.46989/001c.94135. eCollection 2024.
2
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.达雷妥尤单抗单药治疗难治性温抗体自身免疫性溶血性贫血和冷凝集素病。
Blood Adv. 2024 Jun 11;8(11):2622-2634. doi: 10.1182/bloodadvances.2024012585.
3
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.FTL004 是一种抗 CD38 mAb，其与 RBC 的结合可忽略不计，促凋亡活性增强，是治疗多发性骨髓瘤和非霍奇金淋巴瘤的一种新型候选药物。
J Hematol Oncol. 2022 Dec 29;15(1):177. doi: 10.1186/s13045-022-01395-0.
本文引用的文献
1
Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia.达雷妥尤单抗，一种治疗多重难治性自身免疫性血细胞减少症的全新方法。
Haematologica. 2021 Dec 1;106(12):3198-3201. doi: 10.3324/haematol.2021.279232.
2
Diverse functional autoantibodies in patients with COVID-19.COVID-19 患者中的多种功能性自身抗体。
Nature. 2021 Jul;595(7866):283-288. doi: 10.1038/s41586-021-03631-y. Epub 2021 May 19.
3
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.达雷妥尤单抗用于清除T细胞/CD19/CD22阴性急性淋巴细胞白血病高危晚期复发时的微小残留病
Leukemia. 2020 Jan;34(1):293-295. doi: 10.1038/s41375-019-0548-z. Epub 2019 Aug 21.
4
Evaluation of the safety and efficacy of daratumumab outside of clinical trials.评估达雷妥尤单抗在临床试验之外的安全性和疗效。
Int J Hematol. 2019 Jun;109(6):665-672. doi: 10.1007/s12185-019-02648-4. Epub 2019 Apr 8.
5
Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.达雷妥尤单抗治疗复发/难治性费城染色体阳性急性淋巴细胞白血病
Haematologica. 2018 Oct;103(10):e489-e490. doi: 10.3324/haematol.2018.197640. Epub 2018 Jun 28.
6
Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?达雷妥尤单抗在移植后难治性T细胞急性淋巴细胞白血病前沿——一种值得采用的策略？
Bone Marrow Transplant. 2018 Nov;53(11):1487-1489. doi: 10.1038/s41409-018-0222-5. Epub 2018 Jun 8.
7
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.达雷妥尤单抗治疗 T 细胞急性淋巴细胞白血病的临床前疗效。
Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
8
Adult Primary Immune Thrombocytopenia: Spleen Histology Findings and Outcomes According to Rituximab Use Based on Analysis of 41 Cases.成人原发免疫性血小板减少症：基于 41 例分析的利妥昔单抗使用与脾脏组织学表现和结局的相关性。
Am J Surg Pathol. 2018 Mar;42(3):401-412. doi: 10.1097/PAS.0000000000000994.
9
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.达雷妥尤单抗可清除CD38+免疫调节细胞，促进T细胞扩增，并使多发性骨髓瘤中的T细胞库发生偏移。
Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.
10
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.靶向血液系统恶性肿瘤及其他疾病中CD38的单克隆抗体。
Immunol Rev. 2016 Mar;270(1):95-112. doi: 10.1111/imr.12389.
Zotero 插件